Shanghai Rendu Biotechnology Co. Ltd. A (688193) - Total Liabilities

Latest as of March 2026: CN¥65.45 Million CNY ≈ $9.58 Million USD

Based on the latest financial reports, Shanghai Rendu Biotechnology Co. Ltd. A (688193) has total liabilities worth CN¥65.45 Million CNY (≈ $9.58 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 688193 asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Shanghai Rendu Biotechnology Co. Ltd. A - Total Liabilities Trend (2019–2025)

This chart illustrates how Shanghai Rendu Biotechnology Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 688193 current and non-current assets.

Shanghai Rendu Biotechnology Co. Ltd. A Competitors by Total Liabilities

The table below lists competitors of Shanghai Rendu Biotechnology Co. Ltd. A ranked by their total liabilities.

Company	Country	Total Liabilities
Alpine Income Property Trust, Inc. NYSE:PINE	USA	$414.62 Million
Provident Agro Tbk JK:PALM	Indonesia	Rp4.70 Trillion
RichWave Technology Corp TW:4968	Taiwan	NT$854.24 Million
Corby Spirit and Wine Limited TO:CSW-A	Canada	CA$193.89 Million
RF Acquisition Corp II Ordinary Shares NASDAQ:RFAI	USA	$58.92 Million
Soechi Lines Tbk JK:SOCI	Indonesia	Rp224.96 Million
Singer Thailand Public Company Limited BK:SINGER	Thailand	฿1.71 Billion
Valid Soluções S.A SA:VLID3	Brazil	R$1.14 Billion

Liability Composition Analysis (2019–2025)

This chart breaks down Shanghai Rendu Biotechnology Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 688193 net asset quality score to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	14.97	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.07	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.07	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Shanghai Rendu Biotechnology Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Shanghai Rendu Biotechnology Co. Ltd. A (2019–2025)

The table below shows the annual total liabilities of Shanghai Rendu Biotechnology Co. Ltd. A from 2019 to 2025.

Year	Total Liabilities	Change
2025-12-31	CN¥76.26 Million ≈ $11.16 Million	-7.54%
2024-12-31	CN¥82.48 Million ≈ $12.07 Million	-10.32%
2023-12-31	CN¥91.97 Million ≈ $13.46 Million	-27.77%
2022-12-31	CN¥127.34 Million ≈ $18.63 Million	+40.15%
2021-12-31	CN¥90.86 Million ≈ $13.30 Million	-5.11%
2020-12-31	CN¥95.75 Million ≈ $14.01 Million	+163.00%
2019-12-31	CN¥36.41 Million ≈ $5.33 Million	--

About Shanghai Rendu Biotechnology Co. Ltd. A

SHG:688193 China Diagnostics & Research

Market Cap

$267.08 Million

CN¥1.83 Billion CNY

Market Cap Rank

#15478 Global

#4551 in China

Share Price

CN¥45.55

Change (1 day)

+0.82%

52-Week Range

CN¥40.38 - CN¥61.67

All Time High

CN¥63.91